Aryeh Jason 4
4 · LIGAND PHARMACEUTICALS INC · Filed Dec 8, 2025
Insider Transaction Report
Form 4
Aryeh Jason
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-08$69.51/sh+2,034$141,383→ 71,323 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-12-08−2,034→ 0 totalExercise: $69.51Exp: 2026-05-23→ Common Stock (2,034 underlying)
Holdings
- 51,594(indirect: Indirect)
Common Stock
- 5,025(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
- [F2]This Option was previously reported as a Grant of 2,329 shares, which vested in full on May 23, 2016, at an exercise price of $119.3000 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.